NEW YORK – Nonprofit research organization RTI International said Tuesday that it has inked a partnership with digital PCR developer Codetta Bio.
As part of the collaboration, RTI is investing an undisclosed amount in Codetta Bio along with other investors, such as Anzu Partners and Genoa Ventures.
RTI said the collaboration and investment will allow Codetta to scale its operations, expand its workforce, further enhance the capabilities of its technology, and develop new biomarker assays. Meanwhile, by integrating Codetta's multiomic technology into its research efforts, RTI aims to enhance its scientific research in the life sciences.
"Our collaboration with Codetta Bio will enable RTI to further support our clients in advancing knowledge and addressing complex challenges to improve human health," Dana Hancock, RTI's senior VP of analytics practice area, said in a statement. "The company's parallel data generation provides a more streamlined approach to analyzing multiple datasets, and the RTI team will conduct a pilot study to inform how we can incorporate this technology into future studies of how biology influences disease and treatment outcomes."
Based in Morrisville, North Carolina, Codetta Bio has been commercializing a digital spatial PCR (dsPCR) platform with multiplex and multiomic capabilities, based on a microfluidic technology developed at the University of North Carolina at Chapel Hill. The company raised $15 million in Series A financing in April 2022.